Hims & Hers Health (HIMS) Net Cash Flow Growth (3y) (2022 - 2026)
Hims & Hers Health (HIMS) Net Cash Flow Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 32.03% |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 28.99% |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 37.89% |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | -49.94% |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 37.74% |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | -41.05% |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | -62.71% |
| 10 | Hims & Hers Health | 6.44 Bn | 5.69 Bn | 396.79 Mn | -59.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -59.10% |
| Dec 31, 2025 | -120.55% |
| Sep 30, 2025 | -545.36% |
| Jun 30, 2025 | 400.34% |
| Mar 31, 2025 | 62.23% |
| Dec 31, 2024 | 98.88% |
| Sep 30, 2024 | 41.79% |
| Jun 30, 2024 | 8.19% |
| Mar 31, 2024 | -47.92% |
| Dec 31, 2023 | 84.44% |
| Sep 30, 2023 | 7.04% |
| Jun 30, 2023 | 58.18% |
| Mar 31, 2023 | -60.75% |
| Dec 31, 2022 | -111.04% |
| Sep 30, 2022 | 17.84% |